Physician profile
Ryan Crowder
NPI 1558784728
$8,568.46
in general payments reported to CMS, 2019-2025
23 companies · $4,668 in 2025
The $4,668 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $593 · 2022: $1,040 · 2023: $1,042 · 2024: $1,224 · 2025: $4,668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,113 · Consulting Fee: $2,200 · Travel and Lodging: $1,172 · Education: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,112.64 |
| Consulting Fee | $2,200.00 |
| Travel and Lodging | $1,171.63 |
| Education | $450.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $4,556.38 | 2022-2025 | Winlevi, Absorica Ld, Ilumya |
| Novartis Pharmaceuticals Corporation | $960.39 | 2021-2025 | |
| Abbvie INC. | $777.02 | 2021-2025 | |
| Janssen Biotech, INC. | $488.17 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $411.53 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $362.90 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $164.34 | 2023-2024 | Sotyktu |
| Pfizer INC. | $128.24 | 2022-2025 | |
| Amgen INC. | $116.37 | 2023-2025 | Otezla |
| Organogenesis INC. | $114.16 | 2024 | Novachor |
| Janssen Scientific Affairs, LLC | $81.82 | 2022 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Incyte Corporation | $53.50 | 2023-2025 | Opzelura |
| Allergan, INC. | $49.19 | 2022 | |
| Krystal Biotech INC | $47.62 | 2024 | Vyjuvek |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $29.33 | 2023 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.21 | 2023-2024 | Spevigo |
| Vyne Pharmaceuticals INC. | $26.50 | 2021 | |
| Organon LLC | $24.98 | 2025 | Vtama |
| Regeneron Healthcare Solutions, INC. | $22.13 | 2022 | |
| Arcutis Biotherapeutics, INC. | $18.69 | 2024 | Zoryve |
| Ucb, INC. | $14.72 | 2021 | |
| Genentech USA, INC. | $12.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Crowder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.